Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Summary

This is a randomized, multicenter, open, controlled Post-Marketing Study. 396 patients who were histopathology or exfoliated cell pathology of pleural and ascites confirmed with epithelial ovarian cancer/fallopian tube/peritoneal cancer were enrolled in this study. The subjects will be randomly assigned to one of the two treatment groups at a 1: 1 ratio, and the stratification factors included: chemotherapy type (adjuvant chemotherapy/neoadjuvant chemotherapy), residual disease after surgery (\>1cm, \<1cm, no primary surgery), stage (Ic, II, III or IV), pathological typing, Eastern Cooperative Oncology Group performance status (0 to 1 or 2), BRCA1/2 gene mutation.

Timeline

Start

2019-03-19

Primary completion

2024-03-31

Completion

2024-03-31

Publications

• Shen Y, Tu N, Kong B, Xia B, Zou Y, Yin R, Li Q, Yue Y, Kang S, Wang K, He L, Wang S, Meng Y, Qu P, Huang X, Guo R, Yan P, Pan M, Cheng W, Lou G, Wang Z. Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial. Ther Adv Med Oncol. 2026 Feb 16;18:17588359261420402. doi: 10.1177/17588359261420402. eCollection 2026.

Drugs

Indications

No indication recorded.